

Predictive Medicine by Cytomics

[Cell Biochemistry Group \(1960-2006\)](#)

- [Max-Planck-Institut für Biochemie, Martinsried](#)

Individualized prediction of disease progression and outcome

(Evidence Based Medicine at the Cellular Level)

- [Cell Biochemistry](#) ([PDF](#))


• = external links

1. Aims and Potential

1.1 Pharmaceuticals are typically developed according to *best group (cohort) efficiency*. Once approved they are applied to similar groups of patients. Some patients may, however, not benefit from a presently optimal therapy and are potentially harmed by unwanted therapeutic side effects (adverse drug reactions (ADRs) despite the improved *prognosis* (=group future) of the entire patient group. This is suboptimal. Accurate *predictions* for the reactivity of the *individual patient* in such groups prior to therapy onset constitute therefore a *primordial goal* of [predictive medicine](#) by [cytomics](#). Individualized prediction of disease progression (disease course prediction, outcome prediction) will improve *overall therapeutic efficiency*, better comply with the "[primum nil nocere](#)" principle in medicine and meet the *central patient interest* to be *cured* of disease by an *individually optimized therapy*.

1.2 *Predictive medicine by cytomics (molecular cell system analysis) (fig.1)* aims at > 95% or higher accuracies for therapy related disease course or outcome predictions in individual patients by differential [data pattern classification](#) (*predictive differentials, predictive differential classification*) of molecular cell phenotypes or other molecular measurements in patients. Cells constitute the *elementary function units* of cell systems ([cytomes](#)), organs and organisms. *Diseases* are caused by molecular changes in cells. This means for the detection of early disease processes: ***cells know it first.***

Cytomics as system approach



Cytometry measurements can detect such altered *molecular cell phenotypes* resulting from *genotype* and *exposure* influences. *Disease specific molecular patterns* of immune *indicator cells* like cellular or humoral responses of lympho-/monocytes or granulocyte activation in blood or other body fluids can be probed in case disease inducing cells are not accessible. **fig.1** [System cytometry](#) and cell systems biology

Similar diseases may result from high genotypic susceptibility and low exposure to external influences or alternatively from low genotypic susceptibility at high exposure. *High* genotypic diversity in man at a comparatively *low* number of possible diseases emphasizes the *potential* of *molecular cell phenotypes* as *diagnostic*, *therapy guiding* and *outcome prediction* indicators in individual patients. It may be more promising to therapeutically address disease specific *molecular cell phenotypes* instead of trying to cure patients according to *individual genotype* to reduce the number of potential therapies.

It is in any case *questionable* whether future *disease occurrence* can be predicted from *genotypes alone*, at a time where the *future exposure history* of an individual is still unknown. Exposure to external influences is an important disease promoter as evidenced for example by the non uniform occurrence of *morbus Parkinson* in identical twins ([ref.1,2](#)). Altered *molecular cell phenotypes* may, even in this case, provide *earlier* information about *future disease occurrence* than genotype determination alone.

1.3 Altered molecular cell phenotypes are determined as *differential* classification masks following iterative selection of the most discriminatory [triple matrix patterns](#) between diseased and healthy patients. The optimization process provides *disease* and *patient classification masks* ([rightmost table columns](#)). They represent direct or indirect *molecular equivalents* of *disease processes*. Classification masks can be established for diseased but also disease associated inflammatory immune cells. Either patterns may *vary* to a certain degree from patient to patient due to different combinations of genotype and exposure influences. This does, however, not influence the accuracy of the [robust classification process](#). The *individually optimal therapy* (*individualized, personalized medicine*) can be selected by data pattern classification of patient groups *stratified* for example according to Kaplan-Meier. The presented concept of personalized medicine concerns the care of *diseased patients* or of persons during *disease development*. [Data patterns](#) classifiers are suitable for interlaboratory standardization.

1.4 Patients with a prediction for "*disease aggravation*" may convert under therapy within some time to "*non-complication*" patients such as e.g. in [intensive care medicine](#). The early detection of disease aggravation or amelioration provides a [lead time](#) for preventive therapy onset or for therapy reduction (preventive medicine).

1.5 Therapeutic [lead time](#) may increase overall therapeutic efficiency by the prevention or reduction of disease induced irreversible tissue damage or of unwanted therapeutic side effects. It may also permit to identify risk patients *prior* to disease declaration like in asthma,

rheumatic diseases or diabetes. This may help to *delay* disease outbreak and *reduce* complication rates as an important practical consequence.

1.6 Accuracy levels for individualized predictions of disease progression can be increased in principle from presently around 95% to 99% or higher upon merging the most informative parameters from different studies into the disease classification masks ("*disease signatures*"). The *knowledge extraction* by data pattern classification is independent of mathematical assumptions concerning the value distribution of parameters, and the optimal classification is obtained unsupervised that is in an automated way with high certainty for the selection of the correct data pattern. The classification is comparatively [robust](#) against the misclassification of random statistical aberrations as true aberrations. It uses *discriminatory* data patterns *without statistics* or *correlative* tree classification.

1.7 The two-step research strategy consists of **i)** *hypothesis-driven (deductive approach)* determination of experimental *molecular cell phenotype* parameters of diseased and healthy individuals, followed by **ii)** *hypothesis-free* differential data pattern classification (analysis, mining) for all investigated cells in their full *heterogeneity*.

The use of healthy patients as *reference groups* permits the elaboration of [standardized classifiers](#) (*periodic system of cells*) by the combined reclassification of the most discriminatory parameters of several experimental approaches, performed under different hypotheses (*inductive approach*). Non cellular molecular parameters for example from blood serum, urine or liquor may be additionally included in the analysis. Data patterns with more and more discriminatory efficiency are obtained in this way (*autofocusing*). This may permit to identify new disease associated *molecular hotspots* ("*observing molecular medicine*"), being otherwise *inaccessible to hypothesis development* due to the lack of preexisting knowledge.

This *concept* and *data driven* molecular *top-down* approach is at the beginning comparatively *independent* of prior knowledge about the ultimate molecular causes of disease. It is patient oriented and reduces the use of *hypothesis driven* systematic perturbations of cellular *model systems* to acquire knowledge about disease affected molecular pathways and to subsequently investigate these pathways by bottom-up *systems biology*. Investigations on disease mechanisms are driven by hypothesis development from patient *discriminatory data patterns*.

1.8 Once a certain molecular knowledge has been accumulated, disease inducing molecular pathways can be explored by *retrograde molecular analysis (molecular reverse engineering)* of molecular cell phenotype differentials at the *cell system level*. The pathways can be mathematically modeled (*biomedical cell systems biology*) to further increase the predictive capacity. It is likely that new target molecules and lead structures for *drug discovery* will be detected by *hypothesis-free* data pattern classification due to its capacity to address *unknown molecular knowledge spaces*. In this sense [cytomics](#) represents an entry to *biomedical cell systems biology*.

1.9 The described classification concept *concentrates* the differentially most informative molecular cell parameters as *specific [disease classification masks](#)* containing typically between [5](#) and 30 parameters. It does *not* lead to the determination of ever increasing parameter sets generating frequently *interpretation* difficulties at the individual patient level. An initial goal of this effort is to build a system of standardized, inter hospital exchangeable

and individually predictive data classifiers for patients, possibly within the framework of a [human cytome project](#).

The *potential* of the concept consists in its general applicability to various areas of clinical or ambulant medicine as illustrated below (**chapter 2**) by [collaborative projects](#) with individual hospitals and institutions as well as within the framework of the European Working Group on Clinical Cell Analysis (• [EWGCCA](#)) in the context of clinical cytomics. The apparent challenge is to advance this effort to the patient level in a multistep effort of scientists, clinicians and industry as proposed in the context of the [human cytome project](#) ([PPT](#), [ref181](#), [ref175](#), [ref170](#), [concepts](#), [definitions](#), [cytomics references](#)) or in the establishment of a *periodic system* of cells with stem cells or other cell compartments as reference. Despite resemblance in name, this concept differs significantly from the earlier concept for a • [plant periodic cell system](#).

A human cytome project may lead to the elaboration of a **standardized molecular disease classification system** characterized to an essential part by *individually predictive data patterns*. The number of human diseases is in the *hundreds* or *thousands*, that is significantly *inferior* to the several billions of individuals on this planet. Many diseases manifest in multitudes of *ethnically* and *genetically* different patients with different disease histories and exposure to environmental influences during their lifetime. This leads to *heterogeneities* in therapy response like in rheumatoid diseases or malignancies. *Clinical medicine* tries to cope with this situation by pretherapeutic *patient stratification* to determine as good as possible the *most susceptible* patients. A *standardized molecular disease classification system* based on [standardized diagnostic or predictive molecular data patterns](#) has the potential to define diagnostic entities *more precisely*, including therapy related [disease outcome predictions](#) for individual patients.

2. Individualized prediction of disease progression and outcome (Medical Cytomics, Clinical Cytomics)

== **Flow Cytometry:** ==

- [outcome prediction for high risk AML patients](#)
- [disease activity and prediction of therapeutic efficiency in SLE patients](#)
- [outcome prediction for sepsis patients](#)
- [preoperative identification of risk patients for postoperative effusion and edema \(POEE\) in children cardiac surgery](#)
- [risk assessment for overtraining syndrome in competition cyclists](#)
- [risk assessment for myocardial infarction](#)
- [classification of leukemia and lymphoma](#)
- [classification of immunophenotypes and clinical chemistry parameters in juvenile asthma](#)
- [staging of HIV patients from immunophenotypes](#)

== **CyTOF Data Classification:** ==

- [please submit examples !](#)

== **RNA Expression Arrays:** ==

- [outcome prediction for high risk DLBCL patients](#)

== **Clinical Parameters** ==:

- [prognosis of melanoma patients](#)
- [influenza or corona virus infections: salicylate and hyperthermia during the incubation period](#)

3. Non Medical Data Classification

- [microplankton classification in ocean waters](#)

4. [Timeline: Evolution of Concept](#)

5. [Public Interest](#)

6. References

1. *CM Tanner, R Ottman, SM Goldman, J Ellenberg, P Chan, R Mayeux JW Langstorf.* Parkinson disease in twins: an etiologic study. JAMA (1999) **281**:341-346.
2. *K Wirdefeld, M Gatz, ChA Reynolds, CA Prescott, NL Pederson.* Heritability of Parkinson disease in Swedish twins: a longitudinal study. Neurobiol Aging **32**(10):1923:e1-1923.e8.doi:10.1016/j.neurobiolaging.2011.02.017.

-
- [< Cell Biochemistry](#)
-

Off-line Internet, a time saver !

Download the ZIP file: **classim1.zip** containing all Cell Biochemistry pages for example into directory: **d:\classimed**, unzip into the same directory, enter the address: **file:///d:/classimed/cellbio.html** into the URL field of the Internet browser to directly access text & figures on your harddisk free of network delays (further [information](#)).

Impressum

© 2024 [G.Valet](#)

Mail

Internet: <https://www.classimed.de>

last update: Jan 04,2023

first display: Jan 10,1995
